NuQu is intended for the treatment of pain and disability from degenerative disc disease. Fifteen patients from two clinical sites were treated with the therapy, and the authors concluded no one experienced serious or unexpected safety results. The results warrant a further study of the therapy’s benefits.
The study’s lead clinical investigator was Domagoj Coric, MD, a practicing neurosurgeon at Carolina Neurosurgery and Spine Associates and chief of neurosurgery at Carolina Medical Center in Charlotte, N.C.
More Articles on Spine:
Spine Surgery Readmission Rates Not Indicative of Complications
12 Spine Surgeon Leaders With New Hospital Programs
Lateral Locking Cage Approved for Minimally Invasive Spinal Fusion
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.